Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer, GMU Form Proteomic-Based Cancer Biomarker Alliance

NEW YORK, March 28 (GenomeWeb News) - PerkinElmer and George Mason University will begin a five-year research collaboration to develop proteomic technologies and cancer biomarkers, the partners said today.

 

As first reported last week in ProteoMonitor, a GenomeWeb News publication, scientists from both organizations will work together to design new proteomic platforms for biomarker discovery.

 

The new technologies will operate on a "new concept ... that requires both the precise mass and the amino acid sequence of the candidate biomarker," said Emanuel Petricoin of George Mason.

 

The researchers will use PerkinElmer's Bioxpression platform for biomarker candidates and will be validated in clinical trials.

 

Financial details were not provided.

 

The research will focus on stage one lung, ovarian, and breast cancer.

The Scan

Dropped Charges

The US Justice Department has dropped visa fraud charges against five Chinese researchers, according to the Wall Street Journal.

More Kids

The Associated Press says Moderna is expanding its SARS-CoV-2 vaccine study to included additional children and may include even younger children.

PNAS Papers on Rat Clues to Human Migration, Thyroid Cancer, PolyG-DS

In PNAS this week: ancient rat genome analysis gives hints to human migrations, WDR77 gene mutations in thyroid cancer, and more.

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.